SUPAC stands for Scale-Up and Post-Approval Changes, and it refers to a series of FDA guidance documents that tell pharmaceutical manufacturers what testing, documentation, and regulatory filings they need when making changes to an already-approved drug product. If a company wants to move production to a new facility, switch to a different supplier for an inactive ingredient, or scale up from pilot batches to commercial-size batches, SUPAC lays out a structured, tiered framework for doing so without putting patients at risk. The guidelines have been in place since the mid-1990s, and while newer international frameworks are emerging, SUPAC remains a cornerstone of how post-approval changes are managed in the United States.
Why Post-Approval Changes Need Their Own Rulebook
Once the FDA approves a drug product, the manufacturer’s approved application essentially becomes a contract: the product will be made this way, with these ingredients, at this site, using this process. But pharmaceutical manufacturing is not frozen in time. Companies merge, factories close, equipment breaks down, raw-material suppliers change, and demand may require a move from a small production line to a much larger one. Every one of those changes, even seemingly minor ones, can potentially alter how a drug dissolves, how stable it stays on the shelf, or how it behaves in the body.
Before SUPAC, manufacturers faced uncertainty about exactly what data the FDA would want for a given change. Some companies over-filed, submitting expensive bioequivalence studies for changes that probably did not need them. Others under-filed and ran into compliance problems. SUPAC was designed to eliminate that guesswork by sorting post-approval changes into clearly defined categories, each with its own set of requirements. The guidance describes acceptable manufacturing modifications after approval and specifies the regulatory pathway for each type and magnitude of change.1International Journal of Pharmaceutical Sciences. Post-approval changes in site transfer under the U.S. FDA regulatory framework: A comprehensive review
The Four Main SUPAC Guidances
SUPAC is not a single document. It is a family of guidances, each tailored to a different type of dosage form. The differences matter because a tablet behaves nothing like a cream, and the tests needed to verify that a change has not altered the product are entirely different.
- SUPAC-IR (1995): Covers immediate-release solid oral dosage forms, meaning tablets and capsules that release their active ingredient quickly after swallowing. This was the first SUPAC guidance and set the template for those that followed.
- SUPAC-MR (1997): Addresses modified-release solid oral dosage forms, including extended-release and delayed-release products. Because these products are engineered to release drug over many hours or in a specific part of the gastrointestinal tract, changes to their formulation or manufacturing process carry higher risk and require more rigorous testing.
- SUPAC-SS (1997): Applies to semisolid dosage forms such as creams, ointments, gels, and lotions. These products present unique challenges because their performance depends on factors like particle size, viscosity, and how drug diffuses through the base. In vitro release testing using vertical diffusion cells is considered a key performance-verification tool for these products, and SUPAC-SS provides a framework for setting acceptance criteria for such tests.2PubMed. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms
- SUPAC-ES (1999): An equipment addendum that supplements the earlier guidances with information specific to changes in manufacturing equipment.
Each guidance covers the same broad categories of change but applies different testing expectations based on how the dosage form works and how sensitive it is to process or formulation modifications.
How the Three-Level System Works
The core of SUPAC is a tiered classification system that sorts every post-approval change into one of three levels based on the likelihood that the change will affect the finished product’s quality, safety, or how well it performs in the body.
Level 1 changes are those the FDA considers unlikely to have any detectable impact on the product. These might include very small adjustments to the amount of a coloring agent, a change in the shape of a tablet that does not affect its dissolution, or minor equipment upgrades that do not alter the manufacturing process in a meaningful way. Level 1 changes typically require only minimal documentation, and the manufacturer can report them in its next annual report to the FDA rather than filing a separate supplement.
Level 2 changes are moderate. They could have a noticeable effect on the product, so additional testing is needed to demonstrate that the change has not caused a problem. For example, increasing the amount of a filler in a tablet by a moderate percentage, or moving production to a new site while keeping the same equipment and process, would generally fall into Level 2. These changes usually require the manufacturer to submit a Changes Being Effected (CBE) supplement or a CBE-30 supplement, depending on the specific nature of the change. The manufacturer may begin distributing the changed product before the FDA completes its review, but must have the supporting data in hand.
Level 3 changes are the most significant. They are likely to have a meaningful impact on the product and require the most rigorous documentation, often including in vivo bioequivalence studies to prove the changed product still delivers the same amount of drug to the body in the same way. Moving to a completely different manufacturing process or making large-scale changes to the formulation composition would land in Level 3. These changes require a Prior Approval Supplement (PAS), meaning the manufacturer cannot implement the change or distribute the modified product until the FDA has reviewed and approved the submission.
What Categories of Change SUPAC Addresses
Within each guidance, changes are grouped into four main categories. Understanding which category a particular modification falls into is the first step in determining what level it lands on and what data will be needed.
The first category is components and composition. This covers changes to the inactive ingredients in a formulation, such as switching from one brand of microcrystalline cellulose to another, adjusting the percentage of a lubricant, or adding a new coating material. The sensitivity of the dosage form to these changes varies widely. An immediate-release tablet might tolerate a small excipient swap with little consequence, while a modified-release product that relies on a specific polymer ratio to control drug release could be thrown completely off by the same kind of change.
The second category is manufacturing site changes. If a company wants to make a product at a different factory, SUPAC outlines what is required depending on how different the new site is from the original. A move within the same campus or building is treated differently from a move to a completely new facility across the country or in another region.
The third category is changes in batch size. Scaling up from a small batch to a much larger one, or occasionally scaling down, can affect mixing uniformity, heat transfer during drying, compression forces, and other process parameters. SUPAC defines what multiple of the original batch size can be handled at each level.
The fourth category is manufacturing process and equipment changes. Switching from a wet granulation process to direct compression, replacing one type of blender with another, or changing the speed or temperature parameters of a process step all fall here. These changes can be subtle, but because the physical handling of powder, granules, or semisolid bases directly affects the final product, they demand careful evaluation.
Dissolution Testing as the Workhorse of SUPAC
For solid oral dosage forms, dissolution testing is the primary tool SUPAC relies on to demonstrate that a change has not affected how the product releases its active ingredient. At Levels 1 and 2, in vitro dissolution profiles often serve as the critical evidence. The idea is straightforward: if the modified product dissolves in the same pattern as the original, there is good reason to believe it will behave the same way in the body, potentially making an expensive human bioequivalence study unnecessary.
SUPAC specifies when a simple single-point dissolution test is sufficient and when a full multi-point dissolution profile comparison is needed. For profile comparisons, the similarity factor (commonly known as f2) is the standard metric. An f2 value of 50 or higher indicates that two dissolution profiles are similar enough to be considered equivalent. This approach has been widely adopted, but it is worth noting that global regulatory bodies do not all apply the f2 calculation in the same way. International expectations for dissolution similarity testing have diverged, with different countries imposing different requirements on sampling time points, number of units tested, and statistical handling of the data. That divergence adds cost and complexity for manufacturers operating in multiple markets.3PubMed Central. Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?
For semisolid dosage forms covered by SUPAC-SS, dissolution testing in the traditional sense does not apply. Instead, in vitro release testing using vertical diffusion cells measures how drug migrates out of the cream, ointment, or gel matrix. This method is considered a performance-verification test analogous to dissolution testing for tablets, and SUPAC-SS provides a framework for evaluating whether the release rate has changed after a manufacturing modification.4PubMed. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms
Where SUPAC Fits in Today’s Regulatory Landscape
SUPAC was groundbreaking when it was introduced, but the pharmaceutical regulatory world has evolved considerably since the 1990s. The most significant recent development is ICH Q12, an international guideline on pharmaceutical product lifecycle management published by the International Council for Harmonisation. ICH Q12 introduces concepts like “established conditions,” which are the specific parameters in an approved application that a manufacturer must maintain unless a formal change is made. It also introduces post-approval change management protocols, which allow manufacturers to pre-agree with regulators on how certain future changes will be handled, reducing uncertainty and review timelines.
ICH Q12 emphasizes that science- and risk-based approaches should guide stability studies and other testing to support post-approval changes, allowing companies to draw on their accumulated knowledge of a product to streamline the change process.5Springer Link. Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes The guideline also created a new pathway for changes to analytical methods, recognizing that the test procedures used to evaluate a drug product also evolve over the product’s lifetime. ICH Q14, published shortly after Q12, provides further guidance on how knowledge gained during analytical method development can feed into the Q12 framework to support scientifically sound post-approval changes to those methods.6Springer Link. The Role of Enhanced Analytical Procedure Development in Facilitating Post-Approval Changes Via Established Conditions
In practice, though, adoption of Q12 has been slow. A 2023 industry survey across dozens of countries found limited implementation of Q12 even among ICH member nations. The survey did find broader adoption of risk-based approaches to categorizing post-approval changes compared to an earlier survey from 2020, which is a step in the right direction. But that shift toward risk-based thinking was not matched by faster approval timelines for manufacturers’ change applications.7PubMed Central. A Global Industry Survey on Post-Approval Change Management and Use of Reliance For companies operating primarily in the U.S. market, SUPAC continues to be the day-to-day reference point, even as the regulatory philosophy it embodies gradually merges with the newer international frameworks.
Common Misconceptions About SUPAC
One of the most frequent misunderstandings is that SUPAC tells you exactly what to do for any conceivable change. It does not. SUPAC provides a framework and examples, but many real-world changes do not fit neatly into one box. A manufacturer might make two Level 1 changes simultaneously that, in combination, have a Level 2 effect. The guidances explicitly note that cumulative effects of multiple changes should be considered, but they do not provide a simple formula for how to do that. Professional judgment, supported by product-specific data, remains essential.
Another misconception is that a Level 1 change requires no work at all. The annual report filing requirement is lighter than a supplement, but the manufacturer still needs internal documentation showing that the change was evaluated, that it meets the Level 1 criteria, and that any required testing (such as stability studies or dissolution testing) was performed and passed. The FDA can and does review annual reports and ask questions. A company that treats Level 1 as “no paperwork needed” is setting itself up for compliance trouble.
A third point of confusion involves bioequivalence studies. Some people assume that any significant change automatically requires a human bioequivalence study. SUPAC actually provides a tiered set of testing options, and for many Level 2 changes, in vitro dissolution data alone can serve as the bridge between the old and new versions of the product. Bioequivalence studies are generally reserved for Level 3 changes and for situations where dissolution testing is not considered a reliable predictor of in vivo performance.
Semisolids and Topicals as a Special Case
Topical products present a genuinely different challenge from oral dosage forms, and SUPAC-SS reflects that. When you swallow a tablet, the key question is whether the drug dissolves and gets absorbed into the bloodstream in the same way. But for a cream or ointment applied to the skin, the drug is supposed to act locally, and measuring blood levels may not tell you much about whether the product works at the site of application. This makes demonstrating equivalence after a change harder.
SUPAC-SS relies on in vitro release testing as a surrogate for in vivo performance, but the testing methodology for semisolids has historically been less standardized than dissolution testing for tablets. Researchers have investigated the reliability and reproducibility of vertical diffusion cell methods and found them useful as a performance-verification tool, though the need for standardized reference products and well-defined acceptance criteria remains an area of active work.8PubMed. Reliability and reproducibility of vertical diffusion cells for determining release rates from semisolid dosage forms For Level 3 changes to topical products, clinical endpoint studies or dermatopharmacokinetic studies may be required, both of which are expensive and time-consuming, giving manufacturers a strong incentive to keep changes within Level 1 or 2 territory when possible.
Practical Tips for Navigating the SUPAC Framework
If you work in pharmaceutical manufacturing or regulatory affairs, a few practical principles make SUPAC easier to apply. First, characterize the change before you make it. Determine which SUPAC guidance applies to your dosage form, identify which category (composition, site, batch size, or process) the change falls into, and then assess what level it reaches. This assessment should be documented internally even if the change turns out to be Level 1.
Second, do not evaluate changes in isolation. If you changed a colorant three months ago and now want to switch excipient suppliers, consider whether the two changes together push you into a higher level than either change would on its own. SUPAC’s tiered system works best when applied to the totality of changes since the last major regulatory filing, not to each change as if it exists in a vacuum.
Third, keep your dissolution or in vitro release data current. Having a robust baseline dissolution profile for your product as originally approved makes it much easier to demonstrate similarity after a change. If you do not have good baseline data, any Level 2 change that requires a profile comparison becomes much harder to support.
Fourth, stay aware of the evolving relationship between SUPAC and the ICH Q12 framework. As the FDA continues to implement Q12 concepts, the way post-approval changes are categorized and reviewed may shift. Companies that invest in developing deeper process understanding and defining their established conditions now will be better positioned to take advantage of streamlined change pathways in the future. The direction of travel is clearly toward more flexible, science-based change management, but the pace of that transition across different regulatory agencies remains uneven.9PubMed Central. A Global Industry Survey on Post-Approval Change Management and Use of Reliance
When SUPAC Does Not Apply
SUPAC covers changes to the chemistry, manufacturing, and controls (CMC) section of an approved application. It does not cover changes to a drug’s labeling, to the clinical sections of an application, or to the indication for which the drug is approved. If a manufacturer discovers a new safety signal that requires a label update, that is an entirely separate regulatory process. Similarly, SUPAC does not apply to investigational drugs still in clinical trials or to products that have not yet been approved.
There are also dosage forms that fall outside the scope of the main SUPAC guidances. Injectable products, inhalation products, and transdermal patches each have their own regulatory considerations for post-approval changes, and while the general philosophy of risk-based tiering still applies, the specific testing requirements differ substantially. For sterile injectable products, for instance, the concern is less about dissolution and more about sterility assurance, particulate matter, and container-closure integrity after a change. Manufacturers of these products rely on a combination of other FDA guidances and general regulatory principles rather than on SUPAC directly.
Biological products, including vaccines and monoclonal antibodies, are another major category that SUPAC does not address. Post-approval changes to biologics are governed by a different set of regulatory expectations because these products are made by living organisms, and small changes to manufacturing conditions can have large and sometimes unpredictable effects on the final product. The concept of comparability exercises for biologics serves a role analogous to SUPAC’s tiered change framework, but the underlying science and testing methods are distinct.